BR112012017382A2 - compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica - Google Patents

compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica

Info

Publication number
BR112012017382A2
BR112012017382A2 BR112012017382A BR112012017382A BR112012017382A2 BR 112012017382 A2 BR112012017382 A2 BR 112012017382A2 BR 112012017382 A BR112012017382 A BR 112012017382A BR 112012017382 A BR112012017382 A BR 112012017382A BR 112012017382 A2 BR112012017382 A2 BR 112012017382A2
Authority
BR
Brazil
Prior art keywords
flaviviridae virus
pharmaceutical composition
inhibitor compounds
virus inhibitor
compounds
Prior art date
Application number
BR112012017382A
Other languages
English (en)
Inventor
Canales Eda
O'neil Hanrahan Clarke Michael
Anthony Morganelli Philip
E Lazerwith Scott
Lew Willard
j watkins William
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43538203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012017382(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BR112012017382A2 publication Critical patent/BR112012017382A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

inibidores de viroses flaviviridae. a presente invenção refere-se a compostos de fórmula (i): e a ésteres e sais farmaceuticamente aceitávies dos mesmos. os compostos, as composições e os métodos fornecidos são úteis para o tratamento de infecções de vírus flaviviridae particularmente infecções de hepatite c.
BR112012017382A 2010-01-15 2011-01-14 compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica BR112012017382A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29557610P 2010-01-15 2010-01-15
US35348110P 2010-06-10 2010-06-10
PCT/US2011/021335 WO2011088345A1 (en) 2010-01-15 2011-01-14 Inhibitors of flaviviridae viruses

Publications (1)

Publication Number Publication Date
BR112012017382A2 true BR112012017382A2 (pt) 2017-12-05

Family

ID=43538203

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017382A BR112012017382A2 (pt) 2010-01-15 2011-01-14 compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica

Country Status (27)

Country Link
US (2) US8513298B2 (pt)
EP (2) EP3219713A1 (pt)
JP (2) JP5868872B2 (pt)
KR (1) KR101727776B1 (pt)
CN (1) CN102712633B (pt)
AP (1) AP3576A (pt)
AR (1) AR080001A1 (pt)
AU (1) AU2011205744B2 (pt)
BR (1) BR112012017382A2 (pt)
CA (1) CA2785567C (pt)
CL (1) CL2012001960A1 (pt)
CR (1) CR20120417A (pt)
EA (1) EA021196B1 (pt)
EC (1) ECSP12012104A (pt)
ES (1) ES2626150T3 (pt)
IL (1) IL220545B (pt)
MX (1) MX2012008211A (pt)
NZ (1) NZ600817A (pt)
PE (1) PE20130281A1 (pt)
PL (1) PL2523950T3 (pt)
PT (1) PT2523950T (pt)
SG (2) SG10201500298PA (pt)
SI (1) SI2523950T1 (pt)
TW (1) TWI491609B (pt)
UY (1) UY33183A (pt)
WO (1) WO2011088345A1 (pt)
ZA (1) ZA201205248B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120051022A (ko) * 2009-07-21 2012-05-21 길리애드 사이언시즈, 인코포레이티드 플라비비리데 바이러스의억제제
BR112012005438A2 (pt) 2009-09-09 2018-03-20 Gilead Sciences Inc inibidores de vírus flaviviridae
ES2543105T3 (es) 2010-01-15 2015-08-14 Gilead Sciences, Inc. Inhibidores de virus flaviviridae
PL2523950T3 (pl) * 2010-01-15 2017-09-29 Gilead Sciences, Inc. Inhibitory wirusów flaviviridae
WO2012087596A1 (en) * 2010-12-20 2012-06-28 Gilead Sciences, Inc. Combinations for treating hcv
DE102011003295A1 (de) * 2011-01-28 2012-08-02 Kiekert Ag Kraftfahrzeugschloss
CA2840445A1 (en) * 2011-07-13 2013-01-17 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses
ME03009B (me) * 2011-09-16 2018-10-20 Gilead Pharmasset Llc Metode za lecenje hcv-a
CN103087052A (zh) * 2011-10-31 2013-05-08 上海壹志医药科技有限公司 噻吩衍生物及其药物用途
CN104703991B (zh) 2012-06-08 2018-03-23 吉利德科学公司 黄病毒科病毒的大环抑制剂
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
ES2656087T3 (es) 2012-06-08 2018-02-23 Gilead Sciences, Inc. Inhibidores macrocíclicos de virus Flaviviridae
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8759544B2 (en) * 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8841340B2 (en) * 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
HUE047777T2 (hu) 2013-01-31 2020-05-28 Gilead Pharmasset Llc Két vírusellenes vegyület kombinációs készítménye
US10190162B2 (en) 2014-10-23 2019-01-29 Complete Genomics, Inc. Signal confinement sequencing (SCS) and nucleotide analogues for signal confinement sequencing
KR20230130175A (ko) 2014-12-26 2023-09-11 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
WO2017192599A1 (en) 2016-05-02 2017-11-09 Florida State University Research Foundation, Inc. Treatment of zika virus infections using alpha-glucosidase inhibitors
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
ES2912035T3 (es) 2016-06-01 2022-05-24 Athira Pharma Inc Compuestos
CA3082191C (en) 2017-12-07 2021-09-21 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN108096562B (zh) * 2017-12-25 2021-05-11 武汉百药联科科技有限公司 20s蛋白酶体抑制剂在制备治疗日本乙型脑炎病毒感染的药物中的用途
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US743729A (en) * 1903-03-02 1903-11-10 William Clark Kirk Work-support for lathes.
US3533088A (en) * 1967-10-31 1970-10-06 Rca Corp Control circuit for memory
US4714839A (en) * 1986-03-27 1987-12-22 Advanced Micro Devices, Inc. Control circuit for disabling or enabling the provision of redundancy
US4721868A (en) * 1986-09-23 1988-01-26 Advanced Micro Devices, Inc. IC input circuitry programmable for realizing multiple functions from a single input
JPH02146195A (ja) * 1988-11-28 1990-06-05 Nec Corp 半導体記憶装置
JPH03214500A (ja) * 1990-01-18 1991-09-19 Sony Corp メモリ装置
JP2575919B2 (ja) * 1990-03-22 1997-01-29 株式会社東芝 半導体記憶装置の冗長回路
US5959445A (en) * 1995-09-29 1999-09-28 Intel Corporation Static, high-sensitivity, fuse-based storage cell
US5861421A (en) 1995-12-21 1999-01-19 Smithkline Beecham Corporation 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds
US6037799A (en) * 1995-12-29 2000-03-14 Stmicroelectronics, Inc. Circuit and method for selecting a signal
US20020002199A1 (en) 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
US20050119332A1 (en) 1998-03-12 2005-06-02 Lone Jeppesen Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
US6175261B1 (en) * 1999-01-07 2001-01-16 Texas Instruments Incorporated Fuse cell for on-chip trimming
US6275063B1 (en) * 1999-08-24 2001-08-14 Micron Technology, Inc. Method and apparatus for limited reprogrammability of fuse options using one-time programmable elements
US6353336B1 (en) * 2000-03-24 2002-03-05 Cypress Semiconductor Corp. Electrical ID method for output driver
OA12622A (en) 2001-06-11 2006-06-12 Shire Biochem Inc Thiophene derivatives as antiviral agents for flavivirus infection.
CA2449999C (en) 2001-06-11 2012-07-31 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
KR100481179B1 (ko) * 2002-09-10 2005-04-07 삼성전자주식회사 퓨즈를 구비한 회로 및 이를 이용한 반도체 장치
JP3884374B2 (ja) * 2002-12-06 2007-02-21 株式会社東芝 半導体装置
NZ540799A (en) 2002-12-10 2008-09-26 Virochem Pharma Inc Compounds and methods for the treatment or prevention of flavivirus infections
DE60332482D1 (de) * 2002-12-10 2010-06-17 Virochem Pharma Inc Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
KR100569585B1 (ko) * 2003-12-05 2006-04-10 주식회사 하이닉스반도체 내부 전원 드라이버 제어 회로
DE10359791A1 (de) 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
US7521473B2 (en) 2004-02-25 2009-04-21 Wyeth Inhibitors of protein tyrosine phosphatase 1B
RU2006138036A (ru) 2004-03-30 2008-05-10 Чирон Корпорейшн (Us) Производные замещенного тиофена в качестве противораковых средств
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
DE102005028077A1 (de) 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
BRPI0610283A2 (pt) * 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
WO2007006091A1 (en) 2005-07-07 2007-01-18 Athlomics Pty Ltd Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
GB0602046D0 (en) 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
BRPI0707870A2 (pt) 2006-02-15 2011-05-10 Sanofi Aventis ariltienopirimidinonas substituÍdas com amino Álcool, processo para sua preparaÇço e seu uso como medicamentos
JP5290186B2 (ja) 2006-11-15 2013-09-18 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染症の治療または予防用のチオフェン類似体
EP2086966B1 (en) 2006-11-17 2011-09-14 GlaxoSmithKline LLC 2-carboxy thiophene derivatives as anti viral agents
PE20120207A1 (es) 2008-12-03 2012-03-31 Presidio Pharmaceuticals Inc Derivados de naftaleno, como inhibidores de hcv ns5a
KR20120051022A (ko) * 2009-07-21 2012-05-21 길리애드 사이언시즈, 인코포레이티드 플라비비리데 바이러스의억제제
BR112012005438A2 (pt) 2009-09-09 2018-03-20 Gilead Sciences Inc inibidores de vírus flaviviridae
CA2781614A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
ES2543105T3 (es) * 2010-01-15 2015-08-14 Gilead Sciences, Inc. Inhibidores de virus flaviviridae
PL2523950T3 (pl) 2010-01-15 2017-09-29 Gilead Sciences, Inc. Inhibitory wirusów flaviviridae
AR081691A1 (es) 2010-06-28 2012-10-10 Vertex Pharma Derivados de tiofeno, metodos para su preparacion y su uso en el tratamiento o la prevencion de infecciones por flavivirus
CA2840445A1 (en) 2011-07-13 2013-01-17 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses

Also Published As

Publication number Publication date
KR101727776B1 (ko) 2017-04-17
TWI491609B (zh) 2015-07-11
CN102712633A (zh) 2012-10-03
MX2012008211A (es) 2012-08-08
CA2785567C (en) 2018-03-27
SG182475A1 (en) 2012-08-30
JP2013517291A (ja) 2013-05-16
EA021196B1 (ru) 2015-04-30
CA2785567A1 (en) 2011-07-21
CL2012001960A1 (es) 2012-10-26
AU2011205744B2 (en) 2015-06-25
EA201290576A1 (ru) 2013-01-30
CN102712633B (zh) 2015-07-29
US20130315861A1 (en) 2013-11-28
EP2523950A1 (en) 2012-11-21
PT2523950T (pt) 2017-06-01
US20110178129A1 (en) 2011-07-21
SI2523950T1 (sl) 2017-06-30
AU2011205744A1 (en) 2012-07-26
TW201134822A (en) 2011-10-16
EP3219713A1 (en) 2017-09-20
AP3576A (en) 2016-02-08
WO2011088345A1 (en) 2011-07-21
ES2626150T3 (es) 2017-07-24
NZ600817A (en) 2014-08-29
JP2016041732A (ja) 2016-03-31
ECSP12012104A (es) 2012-09-28
ZA201205248B (en) 2013-03-27
IL220545A0 (en) 2012-08-30
US8513298B2 (en) 2013-08-20
KR20120101733A (ko) 2012-09-14
JP5868872B2 (ja) 2016-02-24
US9321753B2 (en) 2016-04-26
CR20120417A (es) 2012-11-30
UY33183A (es) 2011-08-31
SG10201500298PA (en) 2015-03-30
PE20130281A1 (es) 2013-03-08
AR080001A1 (es) 2012-03-07
PL2523950T3 (pl) 2017-09-29
AP2012006414A0 (en) 2012-08-31
EP2523950B1 (en) 2017-03-15
IL220545B (en) 2018-02-28

Similar Documents

Publication Publication Date Title
BR112012017382A2 (pt) compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica
BR112012017402A2 (pt) inibidores de vírus de flaviviridae
PH12020550552A1 (en) Inhibitors of hepatitis c virus
BR112014030649A2 (pt) inibidores macrocíclicos da flaviviridae vírus
BR112014030639A2 (pt) inibidores macrocíclicos de vírus flaviviridae
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
EA201201031A1 (ru) Ингибиторы вируса гепатита с
EA201390822A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
EA201290053A1 (ru) Ингибиторы вирусов flaviviridae
EA201500265A1 (ru) Ингибиторы репликации вирусов гриппа
BR112013020042A2 (pt) inibidores de vírus da hepatite c
BR112013028487A2 (pt) inibidores do vírus da hepatite c
BR112013028679A2 (pt) inibidores do vírus da hepatite c
BR112013032049A2 (pt) inibidores do vírus da hepatite c
BR112015007879A2 (pt) inibidores do vírus da hepatite c
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
BR112015021768A2 (pt) inibidores do vírus da hepatite c
BR112018005843A2 (pt) inibidores de calicreína de plasma humano
UA107801C2 (en) Derivatives of thiophene-2-carboxylic acid inhibitors viruses flaviviridae
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements